New Alzheimer's drug aims to clear brain plaques
NCT ID NCT04639050
First seen Nov 01, 2025 · Last updated Jun 22, 2026 · Updated 32 times
Summary
This study tests an experimental drug called RO7126209 (Trontinemab) in people with early to moderate Alzheimer's disease. The drug is given by IV infusion and aims to reduce amyloid plaques in the brain, a hallmark of Alzheimer's. About 241 participants will receive either the drug or a placebo to check safety and how well the drug works.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ALZHEIMERS DISEASE are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Abington Neurological Associates
Abington, Pennsylvania, 19001, United States
-
Advent Health Orlando
Orlando, Florida, 32804, United States
-
Alfred Hospital
Melbourne, Victoria, 3004, Australia
-
Alzheimer's Research and Treatment Center
Stuart, Florida, 34996, United States
-
Alzheimer's Research and Treatment Center - Columbus
Columbus, Georgia, 31904, United States
-
Alzheimer?s Research and Treatment Center
Wellington, Florida, 33414, United States
-
Center for Advanced Research & Education
Gainesville, Georgia, 30501, United States
-
Centro de Investigación Clínica UC-CICUC
Santiago, 8330034, Chile
-
Charter Research - Lady Lake/The Villages
The Villages, Florida, 32162, United States
-
Charter Research - Winter Park/Orlando
Orlando, Florida, 32803, United States
-
Conquest Research, LLC
Winter Park, Florida, 32789, United States
-
Federation of National Public Service Personnel Mutual Aid Associations Tachikawa Hospital
Tokyo, 190-8531, Japan
-
Fundación ACE
Barcelona, 08028, Spain
-
Heidelberg Repatriation Hospital
Heidelberg West, Victoria, 3081, Australia
-
Hospital Clinic i Provincial
Barcelona, 08036, Spain
-
Hospital Clinico Univ de Chile
Santiago, 8380456, Chile
-
Hospital General De Catalunya
Sant Cugat del Vallès, Barcelona, 8195, Spain
-
Hospital Universitario 12 de Octubre
Madrid, 28041, Spain
-
Hospital Universitario Dr. Peset
Valencia, 46017, Spain
-
Hospital Universitario la Fe
Valencia, 46026, Spain
-
Inha University Hospital
Incheon, 22332, South Korea
-
JEM Research LLC
Atlantis, Florida, 33462, United States
-
K2 Medical Research - The Villages
Lady Lake, Florida, 32159, United States
-
K2 Medical Research, LLC
Maitland, Florida, 32751, United States
-
K2 Medical Research-Winter Garden
Clermont, Florida, 34711, United States
-
Keio University Hospital
Tokyo, 160-8582, Japan
-
Kerwin Research Center, LLC
Dallas, Texas, 75231, United States
-
Koseikai Takeda Hospital
Kyoto, 600-8558, Japan
-
NZOZ WCA
Wroc?aw, 53-659, Poland
-
National Hospital Organization Utano National Hospital
Kyoto, 616-8255, Japan
-
Optimus U Corp
Miami, Florida, 33135, United States
-
Osrodek Badan Klinicznych Euromedis
Szczecin, 70-111, Poland
-
Policlínica Guipuzcoa
Donostia / San Sebastian, Guipuzcoa, 20014, Spain
-
Quest Research Institute
Farmington Hills, Michigan, 48334, United States
-
Richmond Clinical Trials
Richmond, British Columbia, V6V 2L1, Canada
-
Samsung Medical Center
Seoul, 06351, South Korea
-
Summit Research Network Inc.
Portland, Oregon, 97210, United States
-
Tokyo Metropolitan Institute for Geriatrics and Gerontology
Tokyo, 173-0015, Japan
-
Toronto Memory Program
Toronto, Ontario, M3B 2S7, Canada
-
UCL Institute of Neurology
London, WC1N 3BG, United Kingdom
-
Yokohama City Minato Red Cross Hospital
Kanagawa, 231-8682, Japan
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
RO7126209 (Trontinemab)
What this could lead to
If successful, this could point toward a treatment that slows or stops Alzheimer's by clearing amyloid plaques from the brain.
What could go wrong
This is an early-phase trial (Phase 1/2) with a small number of participants, so safety and effectiveness are not yet proven. The drug may cause side effects or fail to show benefit.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.